MDT-AP-2584
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36
- os_event
- false
- age_years
- 26
- sex
- M
- new_clusters
- S1
- umap1_2d
- -1.277132819
- umap2_2d
- -10.8936289
- umap1_3d
- -2.433424012
- umap2_3d
- -0.784261202
- umap3_3d
- 5.040490738
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.570
- INFLAMMATORY_RESPONSE+0.540
- INTERFERON_ALPHA_RESPONSE+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- INTERFERON_GAMMA_RESPONSE+0.520
- ANGIOGENESIS+0.490
- ALLOGRAFT_REJECTION+0.480
- IL6_JAK_STAT3_SIGNALING+0.480
- COAGULATION+0.450
- COMPLEMENT+0.410
Top 10 suppressed
- MITOTIC_SPINDLE-0.350
- PROTEIN_SECRETION-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.340
- MYC_TARGETS_V2-0.310
- G2M_CHECKPOINT-0.300
- DNA_REPAIR-0.220
- HEME_METABOLISM-0.220
- MYC_TARGETS_V1-0.180
- PI3K_AKT_MTOR_SIGNALING-0.170
- E2F_TARGETS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0484 | Med | Medulloblastoma | 0.938 |
| 2 | TCGA-77-8131-01A-11R-2247-07 | — | cohortSQ1 | 0.916 |
| 3 | sclc0617_S65.txt | — | cohortMD2 | 0.915 |
| 4 | MDT-AP-2921 | Med | Medulloblastoma | 0.915 |
| 5 | MDT-AP-0410 | Med | Medulloblastoma | 0.912 |
| 6 | MDT-AP-2284 | Med | Medulloblastoma | 0.906 |
| 7 | TCGA-FD-A5BT-01A-11R-A26T-07 | — | — | 0.905 |
| 8 | SRR1313163 | — | D | 0.903 |
| 9 | BS_S9929Z8B | Ganglioglioma | — | 0.903 |
| 10 | ERR2598312 | fetal | fetal | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| COAGULATION | 0.450 | Binimetinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |